Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18
February 14 2022 - 8:00AM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies, today announced that
Jonathan Violin, Ph.D., President and Chief Executive Officer will
participate in a Fireside Chat at the SVB Leerink 11th Annual
Global Healthcare Conference on February 18 at 2:20pm ET.
The live webcast and a replay of the Fireside
Chat can be accessed under “Events” in the Investors section of the
Viridian Therapeutics, Inc. website.
About Viridian Therapeutics,
Inc.
Viridian Therapeutics is a biotechnology company
advancing new treatments for patients suffering from serious
diseases but underserved by today’s therapies. Viridian’s most
advanced program, VRDN-001, is a differentiated monoclonal antibody
targeting insulin-like growth factor-1 receptor (IGF-1R), a
clinically and commercially validated target for the treatment of
thyroid eye disease (TED). Viridian’s second product candidate,
VRDN-002, is a distinct anti-IGF-1R antibody that incorporates
half-life extension technology and is designed to support
administration as a convenient, low-volume, subcutaneous
injection. TED is a debilitating autoimmune disease that
causes inflammation and fibrosis within the orbit of the eye which
can cause double vision, pain, and potential blindness. Patients
with severe disease often require multiple remedial surgeries to
the orbit, eye muscles and eyelids. Viridian is based in Waltham,
Massachusetts.
Investor and Media Contact:John
JordanViridian TherapeuticsVice President, Investor Relations&
Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jul 2023 to Jul 2024